12,097 results match your criteria Haematologica - The Hematology Journal[Journal]


Human stem cells transplanted into the rat stroke brain migrate to spleen via lymphatic and inflammation pathways.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Department of Neurosurgery and Brain Repair, University of South Florida

Despite mounting evidence of a massive peripheral inflammatory response accompanying stroke, the ability of intracerebrally transplanted cells to migrate to the periphery and sequester systemic inflammation remains unexamined. Here, we tested the hypothesis that human bone marrow mesenchymal stromal cells intracerebrally transplanted in the brain of adult rats subjected to experimental stroke can migrate to the spleen, a vital organ that confers peripheral inflammation after stroke. Adult Sprague-Dawley rats received sham or experimental stroke via the one-hour middle cerebral artery occlusion model. Read More

View Article
December 2018
1 Read

Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Institute of Medical Sciences, Ashgrove Road West, University of Aberdeen, UK

Platelet destruction in immune thrombocytopenia is caused by autoreactive antibody and T cell responses, most commonly directed against platelet glycoprotein IIb/IIIa. Loss of self-tolerance in the disease is also associated with deficient activity of regulatory T cells. Having previously mapped seven major epitopes on platelet glycoprotein IIIa that are recognised by helper T cells from patients with immune thrombocytopenia, the aim was to test whether peptide therapy with any of these sequences, alone or in combination, could inhibit responses to the antigen in humanized mice expressing HLA-DR15. Read More

View Article
December 2018
1 Read

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

GlaxoSmithKline;

Lysine specific demethylase 1 (LSD1) is a histone modifying enzyme that suppresses gene expression through demethylation of lysine 4 on histone H3. The anti-tumor activity of GSK2879552 and GSK-LSD1, potent, selective irreversible inactivators of LSD1, has previously been described.1 Inhibition of LSD1 results in a cytostatic growth inhibitory effect in a range of acute myeloid leukemia cell lines. Read More

View Article
December 2018
3 Reads

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Munich.

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response is unknown. Read More

View Article
December 2018
1 Read

Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Department of Hematology, Rigshospitalet, Copenhagen, Denmark;

In chronic lymphocytic leukemia, mutations and deletion of chromosome 17p are well-characterized biomarkers associated with poor progression-free and overall survival following chemoimmunotherapy. Patients harboring low burden mutations with variant allele frequencies of 0.3-15% have been shown to have similar dismal outcome as those with high burden mutations. Read More

View Article
December 2018

Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Cancer Science Institute of Singapore.

Acute leukemia of ambiguous lineage (ALAL) is a rare group of blood cancers that cannot be clearly classified into either myeloid or lymphoid lineage through traditional immunophenotyping (2016 World Health Organization classification). In this study, we performed exome and transcriptome sequencing of 15 diagnosis/relapse samples to identify mutations of this disease. Remarkably, genes involved in DNA repair pathway were frequently mutated and occurred in 80% of the samples. Read More

View Article
December 2018
1 Read

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Universite Paris Descartes, Sorbonne Paris Cite, INSERM U1138, Centre de Recherche des Cordeliers

Therapeutic factor VIII presents with elevated immunogenicity. Despite intensive research in the last decades, the reasons for which 5-30% of patients with hemophilia A (encompassing all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement therapy remain an enigma. Under physiological conditions, endogenous factor VIII is recognized by the immune system. Read More

View Article
December 2018
1 Read

Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

University Hospital Heidelberg, Dept. Medicine V

Increasing evidence suggests that endothelial cell distress is associated with mortality after allogeneic stem cell transplantation and acute graft-versus-host disease. Asymmetric dimethylarginine is an endogenous nitric oxide synthase inhibitor that induces endothelial cell dysfunction. We analyzed the impact of pre-transplant serum levels of asymmetric dimethylarginine on outcome after allogeneic stem cell transplantation. Read More

View Article
December 2018

Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Fred Hutchinson Cancer Research Center.

Survivorship care plans may facilitate long-term care for cancer survivors, but their effectiveness has not been established in hematopoietic cell transplantation recipients. We evaluated the impact of individualized survivorship care plans on patient-reported outcomes among transplant survivors. Adult (≥18 years at transplant) survivors who were 1-5 years post-transplantation, proficient in English, and without relapse or secondary cancers were eligible for this multicenter randomized trial. Read More

View Article
December 2018

Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University.

View Article
November 2018
1 Read

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in haematological malignancies.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

University of Liverpool;

BH3 mimetics are novel targeted drugs with remarkable specificity and potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to increasing doses of Navitoclax (ABT-263), a BH3 mimetic. Read More

View Article
November 2018
5 Reads

First line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;

The aim of this study was to investigate long-term outcome following first line therapy in consecutive chronic lymphocytic leukemia patients in a well defined geographic area (Sweden). All patients diagnosed with chronic lymphocytic leukemia (2007-2013) (n=3672) were identified from national registries, screening of patient files identified all (100%) first line treated (n=1053) and for those, depth analysis was performed. Endpoints were overall response rate, progression-free survival, overall survival and safety. Read More

View Article
November 2018
1 Read

Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

University of Leuven;

Sphingolipids are fundamental to membrane trafficking, apoptosis and cell differentiation and proliferation. KDSR or 3-keto-dihydrosphingosine reductase is an essential enzyme for de novo sphingolipid synthesis, and pathogenic mutations in KDSR result in the severe skin disorder erythrokeratodermia variabilis et progressiva-4. Four of the eight reported cases also had thrombocytopenia but the underlying mechanism has remained unexplored. Read More

View Article
November 2018
1 Read

The population dynamics of haemoglobins A, A, F and S in the context of the haemoglobinopathies HbS and α+thalassaemia in Kenyan infants.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Few studies have described the dynamics of haemoglobin production in African populations with a high prevalence of haemoglobinopathies. We have used the BioRad Variant ClassicTM HPLC method to document the production patterns of the common haemoglobin variants HbA, HbA2, HbF and HbS, stratified by a+thalassaemia genotype, among 15,301 infants recruited to a study on the Coast of Kenya. Notably, we confirm that HbA2 measurements determined using this instrument are unreliable in HbAS and HbSS subjects. Read More

View Article
November 2018
1 Read

The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy;

CD147 is a transmembrane glycoprotein with multiple functions in human healthy tissues and diseases, in particular in cancer. Overexpression of CD147 correlates with biological functions that promote tumor progression and confers resistance to chemotherapeutic drugs. In contrast to solid tumors, the role of CD147 has not been extensively studied in leukemia. Read More

View Article
November 2018
4 Reads

Trypsin encoding PRSS1-PRSS2 variation influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report.

Haematologica 2018 Nov 22. Epub 2018 Nov 22.

Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet;

Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten acute lymphoblastic leukemia trial groups contributed remission samples from patients aged 1.0-17. Read More

View Article
November 2018
5 Reads
5.870 Impact Factor

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Haematologica 2018 Nov 15. Epub 2018 Nov 15.

Ulm University.

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Read More

View Article
November 2018
3 Reads

New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats.

Haematologica 2018 Nov 15. Epub 2018 Nov 15.

Istituto Auxologico Italiano,IRCCS, Milan, Italy;

Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 of β2glycoproteinI in terms of risk of thrombosis and pregnancy complications in patients with antiphospholipid syndrome. To obtain direct evidence for the pathogenic role of anti-domain 1 or anti-domain 4/5 antibodies, we analysed the in vivo pro-coagulant effect of two groups of 5 serum IgG each reacting selectively with domain 1 or domain 5 in LPS-treated rats. Antibody-induced thrombus formation in mesenteric vessels was followed by intravital microscopy and vascular deposition of β2glycoproteinI, human IgG and C3 was analyzed by immunofluorescence. Read More

View Article
November 2018
5 Reads

In vitro and in vivo evaluation of possible pro-survival activities of PGE2, EGF, TPO and FLT3L on human hematopoiesis.

Haematologica 2018 Nov 15. Epub 2018 Nov 15.

University Medical Center Freiburg

Myelosuppression is a major and frequently dose limiting side-effect of anticancer therapy and responsible for most treatment-related morbidity and mortality. In addition, repeated cycles of DNA damage and cell death of hematopoietic stem and progenitor cells, followed by compensatory proliferation and selection pressure, lead to genomic instability and pave the way for therapy-related myelodysplastic syndromes and secondary acute myeloid leukemia. Protection of hematopoietic stem and progenitor cells from chemo- and radiotherapy in patients with solid tumors would reduce both immediate complications and long-term sequelae. Read More

View Article
November 2018
9 Reads

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Haematologica 2018 Nov 15. Epub 2018 Nov 15.

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.

EXPAND (phase 1b, dose-finding study) evaluated the starting dose of ruxolitinib in patients with myelofibrosis with baseline platelet counts of 50-99x10/L. The study consisted of dose-escalation and safety-expansion phases. Based on the baseline platelet counts, patients were assigned to stratum 1 (75-99x10/L) or stratum 2 (50-74x10/L), with the primary objective of determining the maximum safe starting dose; key secondary objectives included safety and efficacy. Read More

View Article
November 2018
8 Reads

Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation.

Haematologica 2018 Nov 15. Epub 2018 Nov 15.

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA;

We determined the incidence of disability related to chronic graft-versus-host disease (bronchiolitis obliterans, grade ≥ 2 keratoconjunctivitis sicca, sclerotic features or esophageal stricture) for 3 categories of alternative donor: cord blood, haplorelated marrow or peripheral blood with posttransplant cyclophosphamide, and unrelated single HLA-allele mismatched peripheral blood. Among 396 consecutive hematopoietic cell transplantation recipients, 129 developed chronic graft-versus-host disease with incidences in each group of 18% for cord blood, 24% for haplorelated, and 55% for unrelated single HLA-allele mismatched peripheral blood; after a median follow-up of 48, 60, and 46 months, respectively, from diagnosis. Disability rates were significantly lower for cord blood (hazard ratio 0. Read More

View Article
November 2018
6 Reads

miRNAs involvement in the pathogenesis of Richter's syndrome.

Haematologica 2018 Nov 8. Epub 2018 Nov 8.

University of Texas, MD Anderson Cancer Center, Houston, TX, USA;

Richter syndrome represents the transformation of the most frequent type of leukemia, chronic lymphocytic leukemia into an aggressive lymphoma. Patients with Richter syndrome have limited response to therapies and dismal survival. The underlying mechanisms of transformation are insufficiently understood and there is a major lack of knowledge regarding the roles of microRNAs that have already proved to be causative for most cases of chronic lymphocytic leukemia. Read More

View Article
November 2018
8 Reads

A new BCR-ABL1 Drosophila model as a powerful tool to elucidate pathogenesis and progression of chronic myeloid leukemia.

Haematologica 2018 Nov 8. Epub 2018 Nov 8.

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy;

The oncoprotein BCR-ABL1 triggers Chronic Myeloid Leukemia. It is clear that the disease relies on the constitutive BCR-ABL1 kinase activity, but not all the interactors and regulators of the oncoprotein are known. We describe and validate a Drosophila leukemia model based on inducible human BCR-ABL1 expression controlled by tissue specific promoters and thought as a versatile tool to perform genetic screens. Read More

View Article
November 2018
5 Reads
5.870 Impact Factor

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14.

Haematologica 2018 Nov 8. Epub 2018 Nov 8.

Dept of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel

The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F positive myeloproliferative neoplasms. We therefore tested the effectiveness of mirabegron, a β-3 sympathomimetic agonist, in a phase II trial including 39 JAK2-V617F positive MPN with a mutant allele burden >20%. Treatment consisted of mirabegron 50 mg daily for 24 weeks. Read More

View Article
November 2018
10 Reads

Gastrointestinal iron excretion and reversal of iron excess in a mouse model of inherited iron excess.

Haematologica 2018 Nov 8. Epub 2018 Nov 8.

Dept. Pathology and Laboratory Medicine, Brown University, Providence, RI, USA;

The current paradigm in the field of mammalian iron biology states that body iron levels are determined by dietary iron absorption, not by iron excretion. Iron absorption is a highly regulated process influenced by iron levels and other factors. Iron excretion is believed to occur at a basal rate irrespective of iron levels and is associated with processes such as turnover of intestinal epithelium, blood loss, and exfoliation of dead skin. Read More

View Article
November 2018
1 Read

Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply.

Haematologica 2018 Nov;103(11):1758-1759

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article
November 2018
1 Read

To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia.

Haematologica 2018 Nov;103(11):1756-1757

Department of Oncology Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA

View Article
November 2018

Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions.

Haematologica 2018 Nov;103(11):1753-1755

Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

View Article
November 2018

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells.

Haematologica 2018 Oct 31. Epub 2018 Oct 31.

Bern University Hospital, University of Bern, Bern, Switzerland;

Diffuse large B-cell lymphoma is the most common malignant lymphoma in adults. By gene-expression profiling, this lymphoma is divided in three cell-of-origin subtypes with distinct molecular and clinical features. Most lymphomas arise sporadically, yet familial clustering is known, suggesting a genetic contribution to disease risk. Read More

View Article
October 2018
2 Reads

Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents.

Haematologica 2018 Oct 31. Epub 2018 Oct 31.

Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University;

Platelets are critical to arterial thrombosis that underlies myocardial infarction and stroke. Activated platelets, regardless of nature of stimulus, initiate energy-intensive processes that sustain thrombus, while adapting to potential adversities of hypoxia and nutrient deprivation within the densely packed thrombus milieu. We report here that stimulated platelets switch their energy metabolism to aerobic glycolysis by modulating enzymes at key checkpoints in glucose metabolism. Read More

View Article
October 2018
1 Read
5.870 Impact Factor

Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1 driven B-cell precursor acute lymphoblastic leukemia.

Haematologica 2018 Oct 31. Epub 2018 Oct 31.

Dept. of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.

Translocation t(12;21), resulting in the ETV6-RUNX1 (or TEL-AML1) fusion protein, is present in 25% of pediatric patients with B-cell precursor acute lymphoblastic leukemia and is considered a first hit in leukemogenesis. A targeted therapy approach is not available for children with this subtype of leukemia. To identify the molecular mechanisms underlying ETV6-RUNX1 driven leukemia, we performed gene expression profiling of healthy hematopoietic progenitors in which we ectopically expressed ETV6-RUNX1. Read More

View Article
October 2018
1 Read

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Haematologica 2018 Oct 31. Epub 2018 Oct 31.

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin.

Unlike unrelated donor registries, transplant centers lack uniform approaches to related donor assessment and deferral. To test whether related donors are at increased risk for donation related toxicities we conducted a prospective observational trial of 11,942 related and unrelated age 18-60. Bone marrow was collected at 37 transplant and 78 National Marrow Donor Program centers and peripheral blood stem cells were collected at 42 transplant and 87 unrelated donor centers in North America. Read More

View Article
October 2018
2 Reads

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.

Haematologica 2018 Oct 31. Epub 2018 Oct 31.

Division of Haematopathology, European Institute of Oncology, Milan, Italy.

Blastic Plasmacytoid Dendritic Cell Neoplasm is a rare and aggressive hematological malignancy currently lacking an effective therapy. To possibly identify genetic alterations useful for a new treatment design, we analyzed by whole-exome sequencing fourteen Blastic Plasmacytoid Dendritic Cell Neoplasm patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program as the most significantly undermined (P<. Read More

View Article
October 2018
9 Reads

Chronic sympathetic driven hypertension promotes atherosclerosis by enhancing hematopoiesis.

Haematologica 2018 Oct 25. Epub 2018 Oct 25.

Baker Heart and Diabetes Institute.

Hypertension is a major, independent risk factor for atherosclerotic cardiovascular disease. However, this pathology can arise through multiple pathways, which could influence vascular disease through distinct mechanisms. An overactive sympathetic nervous system is a dominant pathway that can precipitate in elevated blood pressure. Read More

View Article
October 2018
4 Reads

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.

Haematologica 2018 Oct 25. Epub 2018 Oct 25.

Banc de Sang i Teixits; Institut de Recerca Vall d'Hebron-Universitat Autonoma de Barcelona, Spain;

Large studies in von Willebrand disease patients, including Spanish and Portuguese registries, led to identification of >250 different mutations. It is a challenge to determine the pathogenic effect of potential splice site mutations on VWF mRNA. This study aimed to elucidate the true effects of 18 mutations on VWF mRNA processing, investigate the contribution of next-generation sequencing to in vivo mRNA study in von Willebrand disease, and compare the findings with in silico prediction. Read More

View Article
October 2018
9 Reads
5.870 Impact Factor

CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

Haematologica 2018 Oct 25. Epub 2018 Oct 25.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas;

The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of acute lymphoblastic leukemia/lymphoma patients and assessed the in vitro impact of IMGN632, a conjugate of CD123-binding antibody with a novel DNA-alkylating payload. CD123 expression on leukemic blasts was surveyed in a large cohort of acute lymphoblastic leukemia/lymphoma patients using multicolor/multiparameter flow cytometry. Read More

View Article
October 2018
4 Reads

Disappearance of a strong triple positivity for antiphospholipid antibodies after treatment with Anakinra.

Haematologica 2018 Oct 25. Epub 2018 Oct 25.

CHU Nimes and Université Montpellier, France; I.M. Sechenov University,Moscow, Russia

View Article
October 2018

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: A report of 1578 patients from the Acute Leukemia Working Party of EBMT.

Haematologica 2018 Oct 25. Epub 2018 Oct 25.

Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Tel-Hashomer, Israel.

Primary refractory or relapsed acute myeloid leukemia is associated with dismal prognosis. Allogeneic stem cell transplantation is the only therapeutic option that offers prolonged survival and cure in this setting. In the absence of a matched sibling donor, transplantation from unrelated 10/10 or 9/10 and haploidentical donors are potential alternatives. Read More

View Article
October 2018
11 Reads

Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis.

Haematologica 2018 Oct 18. Epub 2018 Oct 18.

UT MD Anderson Cancer Center

The bone marrow microenvironment, also known as the bone marrow niche, is a complex network of cell types and acellular factors that supports normal hematopoiesis.. For many years, leukemia was believed to be caused by a series of genetic hits to hematopoietic stem and progenitor cells, which transform them to preleukemic and eventually to leukemic cells. Read More

View Article
October 2018
15 Reads